发展中国家晚期帕金森病的脑深部电刺激治疗:来自中国的成本效果研究
该研究采用马尔可夫模型,从患者支付方角度评估中国晚期帕金森病脑深部电刺激(DBS)与最佳药物治疗(BMT)在15年时间 horizon 内的成本效果。结果显示DBS组贴现总成本为¥370 768($56 515.20),BMT组为¥48 808($7 439.68),DBS组额外获得1.51个质量调整生命年,增量成本效果比(ICER)为¥213 544($32 549.96)/质量调整生命年(95%CI,¥208 177.35-218 910.10)。作者结论认为在中国15年时间 horizon 内DBS对晚期帕金森病患者具有成本效果,但无报销时对患者仍是沉重经济负担。
要点
- DBS组贴现总成本¥370 768($56 515.20),BMT组¥48 808($7 439.68)。
- DBS组额外获得1.51个质量调整生命年,ICER为¥213 544($32 549.96)/质量调整生命年。
- 敏感性分析显示DBS相关成本对ICER影响最大。
核心结论
- 在中国15年时间 horizon 内,DBS对晚期帕金森病患者具有成本效果。
- 与发达国家相比,无报销时DBS对患者仍是沉重经济负担。
- 研究结果可能有助于为发展中国家帕金森病临床护理提供基于成本效果的决策信息。
研究设计与样本
- 研究建立马尔可夫模型代表帕金森病的临床进展,预测15年时间 horizon 内的疾病进展和相关医疗成本。
- 从患者支付方角度评估DBS与BMT的成本效果,使用增量成本效果比(ICER)和净效益进行评价。
主要发现
- DBS组贴现总成本为¥370 768($56 515.20)(95%CI,¥369 621.53-371 914.88),BMT组为¥48 808($7 439.68)(95%CI,¥48 502.63-49 114.21)。
- DBS组较BMT组额外获得1.51个质量调整生命年,ICER为¥213 544($32 549.96)/质量调整生命年(95%CI,¥208 177.35-218 910.10)。
- 敏感性分析显示DBS相关成本对ICER影响最大。
- 全国范围净效益BMT为¥33 819($5 154.94)(95%CI,¥30 211.24-37 426),DBS为¥30 361($4 627.85)(95%CI,¥25 587.03-39 433.66)。
- 患者人口学分析显示,更有利的DBS成本效果与较年轻年龄和较轻疾病分期相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The cost-effectiveness of deep brain stimulation (DBS) is more favorable than best medical treatment (BMT) for advanced Parkinson disease (PD) in developed countries. However, it remains unclear in developing countries, where the cost of DBS may not be reimbursed by health care system. OBJECTIVE: To model and evaluate the long-term cost-effectiveness of DBS for advanced PD in China from a patient payer perspective. METHODS: We developed a Markov model representing the clinical progress of PD to predict the disease progression and related medical costs in a 15-year time horizon. The incremental cost-effectiveness ratio (ICER) and net benefit were used to evaluate the cost-effectiveness of DBS vs BMT. RESULTS: DBS treatment led to discounted total costs of ¥370 768 ($56 515.20) (95% CI, ¥369 621.53-371 914.88), compared with ¥48 808 ($7439.68) (95% CI, ¥48 502.63-49 114.21) for BMT, with an additional 1.51 quality-adjusted life years gained, resulting in an ICER of ¥213 544 ($32 549.96)/quality-adjusted life years (95% CI, ¥208 177.35-218 910.10). Sensitivity analysis showed that DBS-related cost has the most substantial impact on ICER. Nation-wide net benefit of BMT and DBS were ¥33 819 ($5154.94) (95% CI, ¥30 211.24-37 426) and ¥30 361 ($4627.85) (95% CI, ¥25 587.03-39 433.66), respectively. Patient demographic analysis showed that more favorable DBS cost-effectiveness was associated with younger age and less severe disease stage. CONCLUSION: DBS is cost-effective for patients with advanced PD over a 15-year time horizon in China. However, compared with developed countries, DBS remains a substantial economic burden for patients when no reimbursement is provided. Our findings may help inform cost-effectiveness-based decision making for clinical care of PD in developing countries.
引用
- Guo X, Feng C, Pu J, et al. Deep Brain Stimulation for Advanced Parkinson Disease in Developing Countries: A Cost-Effectiveness Study From China. Neurosurgery. 2022. PMID: 36729808. doi:10.1227/neu.0000000000002274
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。